Overview

Study of Thyroid Hormones in Prematures

Status:
Withdrawn
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days from birth will reduce by 30% or more (from an estimated 30% to 21%) the proportion of extremely low gestational age subjects with a composite endpoint of "cerebral palsy (CP) or a Bayley III Composite Cognitive Score < 85" at 36 months corrected postnatal age (CA).
Phase:
Phase 3
Details
Lead Sponsor:
New York Medical College
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Treatments:
Hormones
Iodine